Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Key opinion leaders analyze the latest advancements and research findings specific to Non-Clear Cell Renal Cell Carcinoma presented at the American Society of Clinical Oncology 2024 conference.
Key opinion leaders examine the application of tyrosine kinase inhibitors (TKIs) and evaluate first-line therapeutic approaches for renal cell carcinoma.
Background The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) remains unclear in the immuno-oncology (IO) era. The results of two randomized trials, CARMENA and SURTIME, questioned the role and timing of CN. However, despite the latest ...
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. Carlo Messina, Martina ...
Sumanta Kumar Pal, MD, FASCO, highlights key renal cell carcinoma research presented at the 2024 ASCO Annual Meeting, including early data with DFF332.
Combining stereotactic radiosurgery with immunotherapy significantly improves overall survival in patients with renal cell carcinoma and brain metastasis.
Clear cell renal cell carcinoma (ccRCC) accounts for 75% of all kidney cancer cases (3). Most patients with ccRCC harbor von Hippel–Lindau (VHL) gene ...
Metastatic Renal Cell Carcinoma (mRCC), characterised by the spread of tumours beyond the kidneys, poses a particularly aggressive threat. However, ...
Metastatic Renal Cell Carcinoma (mRCC), characterised by the spread of tumours beyond the kidneys, poses a particularly aggressive threat. However, ...
Following the 2024 ASCO Annual Meeting, Martin H. Voss, MD, discusses long-term follow-up data from the phase 2 KEYNOTE-B61 trial investigating pembrolizumab plus lenvatinib in the first-line treatment of advanced non–clear cell RCC.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.